Area of research
Pulmonary and Respiratory Medicine · Immunology
Research interest
Research focused on Trk receptor and Cancer, with related work in Oncology, Acrosome reaction, Tropomyosin. Notable publications include 'Disruption of the principal, progesterone-activated sperm Ca 2+ channel in a CatSper2-deficient infertile patient', 'TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting', and 'Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer'.
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.
HGG-18. Long-term efficacy and safety of larotrectinib in paediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system (CNS) tumours
TRK Fusion Cancer: Patient Characteristics and Survival Analysis in the Real-World Setting
Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.
536P Incidence of fractures in TRK fusion cancer patients treated with larotrectinib
534P Larotrectinib in non-CNS TRK fusion cancer patients: Outcomes by prior therapy and performance status
Larotrectinib versus Prior Therapies in Tropomyosin Receptor Kinase Fusion Cancer: An Intra-Patient Comparative Analysis
542P Growth modulation index (GMI) of larotrectinib versus prior systemic treatments for TRK fusion cancer patients
CTNI-67. EFFICACY AND SAFETY OF LAROTRECTINIB IN PATIENTS WITH TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS: AN EXPANDED DATASET
Growth modulation index (GMI) as a comparative efficacy measure of larotrectinib versus prior systemic treatments for TRK fusion cancer patients.
Disruption of the principal, progesterone-activated sperm Ca <sup>2+</sup> channel in a CatSper2-deficient infertile patient